Sylla Gold Corp. (TSXV:SYG)

Sage Therapeutics Income Statement

Financials in millions CAD. Fiscal year is March - February.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2025	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021
Selling, General & Admin	0.46	0.48	0.65	0.78	0.37	0.06
Operating Expenses	0.7	0.72	1.38	4.31	0.51	0.06
Operating Income	-0.7	-0.72	-1.38	-4.31	-0.51	-0.06
Interest & Investment Income	-	-	-	-	-	0
Currency Exchange Gain (Loss)	-0.03	-0.01	-0.01	-0.03	-0	-
EBT Excluding Unusual Items	-0.73	-0.73	-1.38	-4.34	-0.51	-0.05
Asset Writedown	-	-	-0.03	-	-	-
Other Unusual Items	-	-	-	-	-0	0.12
Pretax Income	-0.73	-0.73	-1.41	-4.34	-0.51	0.07
Net Income	-0.73	-0.73	-1.41	-4.34	-0.51	0.07
Net Income to Common	-0.73	-0.73	-1.41	-4.34	-0.51	0.07
Shares Outstanding (Basic)	54	53	43	34	13	5
Shares Outstanding (Diluted)	54	53	43	34	13	5
Shares Change (YoY)	16.45%	23.02%	26.31%	158.12%	169.18%	-
EPS (Basic)	-0.01	-0.01	-0.03	-0.13	-0.04	0.01
EPS (Diluted)	-0.01	-0.01	-0.03	-0.13	-0.04	0.01
Free Cash Flow	-0.18	-0.22	-0.47	-3.13	-0.67	-0.02
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.09	-0.05	-0.01
EBIT	-0.7	-0.72	-1.38	-4.31	-0.51	-0.06

Updated Jan 16, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.